• Evenementen
  • Webinar
    • Bioprocessing Solutions
      • Increased Downstream Efficiency of mAbs through use of Novel Purification Resin and Additives
      • Viral Clearance breakthrough: Enhancing efficacy and protein stability with a regulatory compliant, novel detergent
      • A novel cell lysis solution with advantageous use characteristics for rAAV manufacturing that can lead to greater downstream recovery by minimizing upstream loss
      • Detergent-based viral inactivation: a case study demonstrating enhanced monoclonal antibody purification
      • Advancing next gen biologic manufacturing by implementing continuous downstream processing platform
      • Adopting novel technologies to improve monoclonal antibody processes
      • Novel approach to purification and viral inactivation of new class of mAbs
      • Risk mitigation and process debottlenecking in continuous biomanufacturing
      • Efficient raw material management for improving bioprocess throughput and flexibility
      • A Changing Landscape for Biopharma
      • Use of a Novel Cell Lysis Buffer for Protection of AAVs and Enhancing Manufacturing Efficiency
      • Understanding monoclonal antibody aggregate behaviour impacting chromatographic process efficiency
      • Improved antibody purification process through use of additives
      • Novel Purification Technologies and Approaches to Maximize Speed, Efficiency and Process Optimization
      • Solutions to optimize biopharma downstream processing
      • Solutions to manage complexity in global single-use supply chain for vaccines manufacturing
      • Process debottlenecking in buffer and media prep using enhanced raw material release/delivery strategies
      • Downstream Process Intensification with Novel Chromatography Resins for Enhanced Monoclonal Antibody Purification
      • Digitalizing biopharma
      • Understanding the critical roles of cGMP chemicals and single-use technologies in cell & gene therapy manufacturing
      • Novel Single-use Solutions for Cell & Gene Therapy Manufacturing
      • Innovative direct dispense technology to ensure in-time delivery and release during continuous biomanufacturing
      • Designing Novel Fluid Sampling Systems for GMP Operations
      • Faster, better, together: Biopharma collaboration trends in the pandemic, and the future of medicine
      • A collaborative ecosystem: Accelerating the commercial manufacturing of novel vaccines and other therapeutics
      • Advancing Adeno-Associated Virus (AAV) Characterization: High-Resolution Techniques for Gene Therapy Applications
    • Chromatography
    • Equipment & instruments
    • Chemicals
    • Quality Control
    • Safety
    • Life Science
    • Controlled Environment

Downstream processing of monoclonal antibodies, which involves multiple chromatographic purification, buffer exchange, and viral inactivation steps, remains the major bottleneck in the manufacturing of these biologic molecules. The evaluation and selection of proper materials and reagents during process development is crucial in developing and optimizing a robust purification process that ensures that in-process impurities from upstream production are removed.

In this presentation, we will discuss the development of a novel affinity chromatography resin, PROchievA^TM. We will show that PROchievA^TM provides enhanced purification of monoclonal antibodies and when used in combination with select additives, enhances the removal of impurities such as host cell protein, DNA, and viruses. Furthermore, we will show how PROchievA^TM provides increased purification of Fc-fusion proteins, and when properly utilized in conjunction with subsequent downstream purification steps, can lead to improvement in overall manufacturing process efficiency of mAbs.

This presentation was given during BPI Europe, Vienna, May 17-19, 2022.

Presented by:

		Ph.D., MBA, Senior Vice President, Research & Development – Biopharma Production, Avantor Nandu Deorkar is Senior Vice President, Biopharma Production Research & Development for Avantor. He is responsible for innovation strategy and planning, and execution of new products and technology development. During his more than 25-year career in research & development, Dr. Deorkar has been leading teams working on various aspects of upstream and downstream bioprocessing, single use systems, chemical/polymer R&D, drug development, formulation, drug delivery technologies, process development, and technology transfer. He has published more than 30 articles and holds more than 20 patents. Dr. Deorkar received Ph.D. from Indian Institute of Technology, Mumbai, India and MBA in Marketing from Fairleigh Dickinson University, Madison, NJ, USA.